The current financial score of Dexcom Inc is 8.91. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 1.31B, representing a year-over-year increase of 13.08%, while its net profit experienced a year-over-year increase of 38.54%.
The current valuation score of Dexcom Inc is 6.55. Its current P/E ratio is 35.40, which is 392.20% below the recent high of 174.26 and 31.72% above the recent low of 24.17.
The current earnings forecast score of Dexcom Inc is 8.60. The average price target is 93.88, with a high of 115.00 and a low of 75.00.
The current price momentum score of Dexcom Inc is 3.06. Currently, the stock price is trading between the resistance level at 90.75 and the support level at 80.45, making it suitable for range-bound swing trading.
The current institutional shareholding score of Dexcom Inc is 10.00. The latest institutional shareholding proportion is 99.64%, representing a quarter-over-quarter decrease of 8.31%. The largest institutional shareholder is Baillie Gifford, holding a total of 14.80M shares, representing 0.90% of shares outstanding, with 14.24% increase in holdings.
The current risk assessment score of Dexcom Inc is 6.55. The company's beta value is 1.44. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.